A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease
Ann Hepatol. 2023 Dec 20:101278. doi: 10.1016/j.aohep.2023.101278. Online ahead of print.ABSTRACTMetabolic dysfunction-associated steatotic liver disease (MASLD), defined by the presence of liver steatosis together with at least one out of five cardiometabolic factors, is the most common cause of chronic liver disease worldwide, affecting around one in three people. Yet the clinical presentation of MASLD and the risk of progression to cirrhosis and adverse clinical outcomes is highly variable. It therefore represents both a global public health threat and a precision medicine challenge. The use of artificial intelligence (...
Source: Annals of Hepatology - December 22, 2023 Category: Gastroenterology Authors: Maria Jimenez-Ramos Timothy J Kendall Ignat Drozdov Jonathan A Fallowfield Source Type: research
From NAFLD to MASLD: When metabolic comorbidity matters
CONCLUSIONS: The new nomenclature of MASLD and SLD is more applicable to identifying significant fibrosis than NAFLD. Patients with three or more cardiometabolic risk factors are at higher risk of fibrosis.PMID:38135250 | DOI:10.1016/j.aohep.2023.101281 (Source: Annals of Hepatology)
Source: Annals of Hepatology - December 22, 2023 Category: Gastroenterology Authors: Shan Hong Lei Sun Yiwei Hao Ping Li Yuling Zhou Xiuxia Liang Julong Hu Hongshan Wei Source Type: research
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease
Ann Hepatol. 2023 Dec 20:101278. doi: 10.1016/j.aohep.2023.101278. Online ahead of print.ABSTRACTMetabolic dysfunction-associated steatotic liver disease (MASLD), defined by the presence of liver steatosis together with at least one out of five cardiometabolic factors, is the most common cause of chronic liver disease worldwide, affecting around one in three people. Yet the clinical presentation of MASLD and the risk of progression to cirrhosis and adverse clinical outcomes is highly variable. It therefore represents both a global public health threat and a precision medicine challenge. The use of artificial intelligence (...
Source: Annals of Hepatology - December 22, 2023 Category: Gastroenterology Authors: Maria Jimenez-Ramos Timothy J Kendall Ignat Drozdov Jonathan A Fallowfield Source Type: research
Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cells
CONCLUSIONS: COL1A1 plays an important role in regulating CCA progression and may act as a promising biomarker and therapeutic target for CCA.PMID:38123132 | DOI:10.1016/j.aohep.2023.101279 (Source: Annals of Hepatology)
Source: Annals of Hepatology - December 20, 2023 Category: Gastroenterology Authors: Shuguang Pan Ying Hu Lang Gan Jiejuan Lai Ping Zheng YuJun Zhang Ling Shuai Yan Jiang Mo Chen Junping Wang Yu He Source Type: research
MiR-326 sponges TET2 triggering imbalance of Th17/Treg differentiation to exacerbate pyroptosis of hepatocytes in concanavalin A-induced autoimmune hepatitis
CONCLUSIONS: Knockdown of miR-326 exerted anti-pyroptosis effects via suppressing TET2 and downstream NF-κB signaling to dampen AIH. We highlighted a therapeutic target in AIH.PMID:38043702 | DOI:10.1016/j.aohep.2023.101183 (Source: Annals of Hepatology)
Source: Annals of Hepatology - December 3, 2023 Category: Gastroenterology Authors: Genglin Zhang Sensen Wu Guangtao Xia Source Type: research
